Bowel perforation in non-small cell lung cancer after bevacizumab therapy

Investigational New Drugs

Volumn 27, Issue 2, 2009, Pages 184-187

  Schellhaas, Elisabeth ^a   Loddenkemper, Christoph ^a   Schmittel, Alexander ^a   Buhr, Heinz J ^a   Pohlen, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bevacizumab; Bowel perforation; Ischemia; Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE ABDOMEN; AGED; ARTICLE; CASE REPORT; CHEMOTHERAPY; CLINICAL FEATURE; COLON RESECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE PERFORATION; ISCHEMIC COLITIS; LAPAROTOMY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS; CHEMICALLY INDUCED DISORDER; LUNG TUMOR;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INTESTINAL PERFORATION; LUNG NEOPLASMS; MALE; PACLITAXEL;

EID: 66949129437     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9162-z     Document Type: Article

References (18)

1. K Abbrederis M Kremer C Schuhmacher 2008 Ischämische Anastomosenperforation im Bereich einer Ileotransversostomie unter Therapie mit Bevacizumab Chirurg 79 351 355 doi:10.1007/s00104-007-1339-z
2. DA August DEP Serrano 2008 "Spontaneous", delayed colon and rectal anastomotic complications associated with bevacizumab therapy J Surg Oncol 97 180 185 doi:10.1002/jso.20938
3. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic non-small cell lung cancer Oncologist 2007 713 718 doi:10.1634/theoncologist.12-6-713
4. C Emmanouilides G Sfakiotaki N Androulakis K Kalbakis C Christophylakis A Kalykaki 2007 Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study BMC Cancer 7 91
5. G Giaccone 2007 The potential of antiangiogenic therapy in non-small cell lung cancer Clin Cancer Res 13 1961 1970 doi:10.1158/1078-0432.CCR-06-2186
6. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 doi:10.1200/JCO.2006.09.6305
7. MS Gordon D Cunningham 2005 Managing patients treated with bevacizumab combination therapy Oncology 69 25 33 doi:10.1159/000088481
8. J Gray J Murren A Sharma S Kelley F Detterbeck G Bepler 2007 Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab J Thorac Oncol 2 571 573 doi:10.1097/JTO.0b013e31805fea51
9. DM Gujral S Bhattacharyya P Hargreaves GW Middleton 2008 Periodontal disease in a patient receiving bevacizumab: a case report J Med Case Reports 2 47
10. ES Han BJ Monk 2007 What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gyn Oncol 105 3 6 doi:10.1016/j.ygyno. 2007.01.038
11. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027 doi:10.1200/JCO.2005.06.081
12. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 doi:10.1056/NEJMoa032691
13. RK Jain RT Tong LL Munn 2007 Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2729 2735 doi:10.1158/0008-5472.CAN-06-4102
14. F Lordick H Geinitz J Theisen A Sendler M Sarbia 2006 Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 1295 1298 doi:10.1016/j.ijrobp.2005.12.004
15. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 doi:10.1056/NEJMoa061884
16. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 1779 1802 doi:10.1016/j.clinthera. 2006.11.015
17. F Simpkins JL Belinson PG Rose 2007 Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient selection Gyn Oncol 107 118 123 doi:10.1016/j.ygyno.2007.06.004
18. JD Wright A Hagemann JS Rader D Viviano RK Gibb L Norris 2006 Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma Cancer 107 83 89 doi:10.1002/cncr.21969